NEW YORK (GenomeWeb News) – Agendia today said that the US Food and Drug Administration has cleared its MammaPrint breast cancer recurrence test for all ages.

Amsterdam-based Agendia said that it is the fourth FDA clearance for MammaPrint over the past three years. It also noted that MammaPrint has been approved in Europe for all ages since 2004.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.